EGFR and lung carcinoma: Recently, it has been demonstrated that mutations in the tyrosine kinase domain region of the EGFR gene in NSCLC predict the response to tyrosine kinase inhibitors [33,34] and enable the identification of the subpopulation of lung cancers that are likely to respond to drugs targeted to EGFRs.